Home » Stocks » ENTA

Enanta Pharmaceuticals, Inc. (ENTA)

Stock Price: $48.91 USD 0.88 (1.83%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
Market Cap 986.59M
Revenue (ttm) 122.47M
Net Income (ttm) -36.17M
Shares Out 19.94M
EPS (ttm) -1.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $48.91
Previous Close $48.03
Change ($) 0.88
Change (%) 1.83%
Day's Open 48.22
Day's Range 47.89 - 49.54
Day's Volume 103,148
52-Week Range 40.22 - 57.58

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 13 hours ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces the Appointment of Brendan Luu as Senior Vice President, Business Development

Business Wire - 2 weeks ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Provide Updates on its R&D Programs and Outlook for 2021 at the 39th Annual J.P. Morgan Healthcare Conference

Business Wire - 3 weeks ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces the Appointment of John P. DeVincenzo, M.D. as Vice President of Translational Virology

Business Wire - 3 weeks ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

Business Wire - 1 month ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces the Appointment of Tara L. Kieffer, Ph.D. as Senior Vice President, New Product Strategy and Development

Seeking Alpha - 2 months ago

Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q4 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 40.22% and -7.80%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead fo...

Benzinga - 2 months ago

Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 431.82% over the past yea...

Business Wire - 2 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2020

Business Wire - 2 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at Upcoming Conferences

Business Wire - 2 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta to Host Conference Call on November 23 to Discuss Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2020

Zacks Investment Research - 2 months ago

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 3 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at the 4th Annual H.C. Wainwright Virtual NASH Investor Conference

Business Wire - 4 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-297, its Highly Potent and Targeted Follow-On Farnesoid X Receptor Agonist for NASH

Business Wire - 4 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Participate in Upcoming September Conferences

Business Wire - 4 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Presents New Data from its Hepatitis B and Non-Alcoholic Steatohepatitis Programs at the Digital International Liver Congress

Business Wire - 5 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Data Presentations at European Association for the Study of the Liver’s (EASL) Digital International Liver Congress

Seeking Alpha - 5 months ago

Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 2.74% and -37.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the...

Benzinga - 5 months ago

Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) were flat after the company reported Q3 results.

Business Wire - 5 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2020 with Webcast and Conference Call Today at 4:30 p.m.

Business Wire - 5 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference 2020

Zacks Investment Research - 5 months ago

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 5 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Host Conference Call on August 4 at 4:30 p.m.

Zacks Investment Research - 8 months ago

Enanta Pharmaceuticals (ENTA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Seeking Alpha - 8 months ago

Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 58.90% and -9.92%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for th...

Zacks Investment Research - 10 months ago

Given the urgent need for curing infected COVID-19 patients, we take a look at companies developing drugs/treatments for the same.

Other stocks mentioned: GILD, LLY, MRNA, REGN, RHHBY, SNY
Benzinga - 10 months ago

The following are the latest biotech announcements from late Thursday and Friday morning on the development of products targeting the coronavirus.

Other stocks mentioned: AYTU, CANF, LJPC, LLY, OPK, RHHBY
Seeking Alpha - 11 months ago

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2020 Results Conference Call February 6, 2020 4:30 PM ET

Zacks Investment Research - 11 months ago

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 10.17% and -11.37%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead fo...

Zacks Investment Research - 11 months ago

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 1 year ago

The small drugmaker depends on royalties from HCV drug Mavyret. And those sales aren't as strong as they used to be.

Other stocks mentioned: ABBV
Seeking Alpha - 1 year ago

Enanta Pharmaceuticals' (ENTA) CEO Jay Luly on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -22.81% and -8.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead f...

Zacks Investment Research - 1 year ago

Enanta (ENTA) posts favorable top-line data from the phase IIa study on its pipeline candidate EDP-305 for treating NASH. Albeit the study meets its goals, the stock declines in after-hours tr...

Seeking Alpha - 1 year ago

Enanta Pharmaceuticals' (ENTA) CEO Jay Luly on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 371.43% and -4.09%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for th...

Zacks Investment Research - 1 year ago

Enanta Pharmaceuticals (ENTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Enanta Pharmaceuticals (ENTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Benzinga - 1 year ago

The thinly traded, small-cap biotech Enanta Pharmaceuticals Inc (NASDAQ:ENTA) announced results Friday from a midstage study.

Seeking Alpha - 1 year ago

Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 322.22% and -1.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for t...

About ENTA

Enanta Pharmaceuticals, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratori... [Read more...]

Industry
Biotechnology
IPO Date
Mar 21, 2013
CEO
Jay Luly
Employees
141
Stock Exchange
NASDAQ
Ticker Symbol
ENTA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for ENTA stock is "Hold." The 12-month stock price forecast is 61.75, which is an increase of 26.25% from the latest price.

Price Target
$61.75
(26.25% upside)
Analyst Consensus: Hold